2487 related articles for article (PubMed ID: 30132304)
1. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
Ruospo M; Palmer SC; Natale P; Craig JC; Vecchio M; Elder GJ; Strippoli GF
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006023. PubMed ID: 30132304
[TBL] [Abstract][Full Text] [Related]
2. Phosphate binders for preventing and treating bone disease in chronic kidney disease patients.
Navaneethan SD; Palmer SC; Vecchio M; Craig JC; Elder GJ; Strippoli GF
Cochrane Database Syst Rev; 2011 Feb; (2):CD006023. PubMed ID: 21328279
[TBL] [Abstract][Full Text] [Related]
3. Potassium binders for chronic hyperkalaemia in people with chronic kidney disease.
Natale P; Palmer SC; Ruospo M; Saglimbene VM; Strippoli GF
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD013165. PubMed ID: 32588430
[TBL] [Abstract][Full Text] [Related]
4. Interventions for metabolic bone disease in children with chronic kidney disease.
Hahn D; Hodson EM; Craig JC
Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD008327. PubMed ID: 26561037
[TBL] [Abstract][Full Text] [Related]
5. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
[TBL] [Abstract][Full Text] [Related]
6. Psychosocial interventions for preventing and treating depression in dialysis patients.
Natale P; Palmer SC; Ruospo M; Saglimbene VM; Rabindranath KS; Strippoli GF
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD004542. PubMed ID: 31789430
[TBL] [Abstract][Full Text] [Related]
7. Antiplatelet agents for chronic kidney disease.
Natale P; Palmer SC; Saglimbene VM; Ruospo M; Razavian M; Craig JC; Jardine MJ; Webster AC; Strippoli GF
Cochrane Database Syst Rev; 2022 Feb; 2(2):CD008834. PubMed ID: 35224730
[TBL] [Abstract][Full Text] [Related]
8. Parenteral versus oral iron therapy for adults and children with chronic kidney disease.
O'Lone EL; Hodson EM; Nistor I; Bolignano D; Webster AC; Craig JC
Cochrane Database Syst Rev; 2019 Feb; 2(2):CD007857. PubMed ID: 30790278
[TBL] [Abstract][Full Text] [Related]
9. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.
Chung EY; Ruospo M; Natale P; Bolignano D; Navaneethan SD; Palmer SC; Strippoli GF
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD007004. PubMed ID: 33107592
[TBL] [Abstract][Full Text] [Related]
10. Low protein diets for non-diabetic adults with chronic kidney disease.
Hahn D; Hodson EM; Fouque D
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD001892. PubMed ID: 33118160
[TBL] [Abstract][Full Text] [Related]
11. Low protein diets for non-diabetic adults with chronic kidney disease.
Hahn D; Hodson EM; Fouque D
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD001892. PubMed ID: 30284724
[TBL] [Abstract][Full Text] [Related]
12. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
Tunnicliffe DJ; Palmer SC; Cashmore BA; Saglimbene VM; Krishnasamy R; Lambert K; Johnson DW; Craig JC; Strippoli GF
Cochrane Database Syst Rev; 2023 Nov; 11(11):CD007784. PubMed ID: 38018702
[TBL] [Abstract][Full Text] [Related]
13. Phosphate-Binding Agents in Adults With CKD: A Network Meta-analysis of Randomized Trials.
Palmer SC; Gardner S; Tonelli M; Mavridis D; Johnson DW; Craig JC; French R; Ruospo M; Strippoli GF
Am J Kidney Dis; 2016 Nov; 68(5):691-702. PubMed ID: 27461851
[TBL] [Abstract][Full Text] [Related]
14. Effects of different phosphate lowering strategies in patients with CKD on laboratory outcomes: A systematic review and NMA.
Sekercioglu N; Angeliki Veroniki A; Thabane L; Busse JW; Akhtar-Danesh N; Iorio A; Cruz Lopes L; Guyatt GH
PLoS One; 2017; 12(3):e0171028. PubMed ID: 28248961
[TBL] [Abstract][Full Text] [Related]
15. Calcium channel blockers for people with chronic kidney disease requiring dialysis.
Mugendi GA; Mutua FM; Natale P; Esterhuizen TM; Strippoli GF
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD011064. PubMed ID: 33000470
[TBL] [Abstract][Full Text] [Related]
16. Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes.
Natale P; Tunnicliffe DJ; Toyama T; Palmer SC; Saglimbene VM; Ruospo M; Gargano L; Stallone G; Gesualdo L; Strippoli GF
Cochrane Database Syst Rev; 2024 May; 5(5):CD015588. PubMed ID: 38770818
[TBL] [Abstract][Full Text] [Related]
17. Interventions for preventing bone disease in kidney transplant recipients.
Palmer SC; Chung EY; McGregor DO; Bachmann F; Strippoli GF
Cochrane Database Syst Rev; 2019 Oct; 10(10):CD005015. PubMed ID: 31637698
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D.
Hara T; Hijikata Y; Matsubara Y; Watanabe N
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD013424. PubMed ID: 34231877
[TBL] [Abstract][Full Text] [Related]
19. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
Lo C; Toyama T; Wang Y; Lin J; Hirakawa Y; Jun M; Cass A; Hawley CM; Pilmore H; Badve SV; Perkovic V; Zoungas S
Cochrane Database Syst Rev; 2018 Sep; 9(9):CD011798. PubMed ID: 30246878
[TBL] [Abstract][Full Text] [Related]
20. Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Hasegawa T; Nishiwaki H; Ota E; Levack WM; Noma H
Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013109. PubMed ID: 33586138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
